These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date Terminated 2005-002857-29 A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease bad-data
Listed as ongoing, but also has a completion date 2007-001421-10 A Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma 2009-02-26 bad-data
Reported results 2011-001084-42 A Randomized, Phase IIb/III Study of Ganetespib (STA-9090) in Combination with Docetaxel versus Docetaxel alone in Subjects with Stage IIIb or IV Non-Small Cell Lung Cancer 2015-11-04 due-trials
Reported results 2012-000558-71 An Open Label Multicenter Phase 2 Window Of Opportunity Study Evaluating Ganetespib (STA-9090) Monotherapy In Women With Previously Untreated Metastic HER2 Positive Or Triple Negative Breast Cancer ... 2015-03-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-000639-16 A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non- Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC) 2014-07-04 bad-data
Reported results 2012-004349-34 A RANDOMIZED, PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA 2015-12-02 due-trials

Related organisations

Over time organisations can merge, or split.

We think Synta Pharmaceuticals Corp. is now effectively part of Madrigal Pharmaceuticals, Inc..